Revance Therapeutics, Inc.

Form 4

Common

Common

Stock

Stock

December 0	1, 2014										
Check the if no long subject to Section 1 Form 4 co Form 5 obligation	RITIES AND EXCHANGE COMMISSION shington, D.C. 20549 RGES IN BENEFICIAL OWNERSHIP OF SECURITIES 6(a) of the Securities Exchange Act of 1934, tility Holding Company Act of 1935 or Section					Number: 3235-0287 Expires: January 31 Estimated average burden hours per response 0.5					
may control See Instr 1(b).	uction	30(h)	of the I	nvestment	t Compai	ny Ac	t of 1940)			
(Print or Type I 1. Name and A Browne L I	8					5. Relationship of Reporting Person(s) to Issuer					
	NCE THERAPE GATEWAY	Middle) UTICS,	3. Date of	te Therapo of Earliest T Day/Year) 2014		c. [R		_X_ Director _X_ Officer (give below)		Owner er (specify	
				Ionth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NEWARK, (City)	CA 94560 (State)	(Zip)	Tab	le I - Non-l	Derivative	Secur		Form filed by M Person ired, Disposed of,			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	ed Date, if	3. Transactic Code (Instr. 8)	4. Securit our Dispose (Instr. 3,	ies Ac	quired (A) D)	· · · · -	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	11/28/2014			P	6,000	A	\$ 16 6699	172,626	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)

1,000 (1)

409

D

See

(2)

footnote

Edgar Filing: Revance Therapeutics, Inc. - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title a	and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orNumber	Expiration D	ate	Amount	of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underly	ing	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securitie	es	(Instr. 5)	Bene
	Derivative				Securities			(Instr. 3	and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									mount		
						Date	Expiration	01 Title N			
						Exercisable	Date	Title Number			
				C 1 W	(A) (D)			of			
				Code V	(A) (D)			S	hares		

Reporting Owners

Reporting Owner Name / Address	Kelationsinps					
	Director	10% Owner	Officer	Other		
Browne L Daniel						

C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK, CA 94560

X

CEO and President

Signatures

/s/ Gordon Ho, Attorney-in-fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1,000 shares acquired by the Reporting Person under the Issuer 2014 Employee Stock Purchase Plan on June 30, 2014.
- (2) These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2